Pretax income is the income that a company earns before paying income taxes. ARS Pharmaceuticals's pretax income for the
three
months ended in Mar. 2024 was $-10.29 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-49.70 Mil.
ARS Pharmaceuticals's pretax margin was %.
During the past 4 years, ARS Pharmaceuticals's highest Pretax Margin was -5.97%. The lowest was -496960.00%. And the median was -1501.53%.
ARS Pharmaceuticals Pre-Tax Income Historical Data
The historical data trend for ARS Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ARS Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, ARS Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's Pre-Tax Income falls into.
ARS Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
ARS Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (NAS:SPRY) Pre-Tax Income Explanation
ARS Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 4 years, ARS Pharmaceuticals's highest Pretax Margin was -5.97%. The lowest was -496960.00%. And the median was -1501.53%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of ARS Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
ARS Pharmaceuticals (ARS Pharmaceuticals) Business Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRY has been successfully added to your 